Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial

• DOI: 10.1186/s12916-018-1163-y
• Publication Date: 2018-09-26T15:00:55Z
• Authors: Ines Stevic; Volkmar Müller; Karsten Weber; Peter A. Fasching; Thomas Karn; Frederic Marmé; Christian Schem; Elmar Stickeler; Carsten Denkert; Marion van Mackel...; Christoph Salat; Andreas Schneeweiss; Klaus Pantel; Sibylle Loibl; Michael Untch; Heidi Schwarzenbach
• Keywords: Neoadjuvant Therapy; Triple-negative breast cancer

The focus of this study is to identify particular microRNA (miRNA) signatures in exosomes derived from plasma 435 human epidermal growth factor receptor 2 (HER2)-positive and triple-negative (TN) subtypes breast cancer (BC).First, miRNA expression profiles were determined the 15 TNBC patients before neoadjuvant therapy using a quantitative TaqMan real-time PCR-based array card containing 384 different miRNAs. Forty-five miRNAs associated with clinical parameters then selected mounted on cards that served for quantification exosomal BC 20 healthy women. Confocal microscopy, Western blot, ELISA used exosome characterization.Quantification 45 showed compared women, 10 entire cohort patients, 13 subgroup 211 HER2-positive BC, 17 224 significantly deregulated. Plasma levels 18 differed between subtypes, 9 them also Exosomal clinicopathological risk factors. In uni- multivariate models, miR-155 (p = 0.002, p 0.003, respectively) miR-301 0.001, best predicted pathological complete response (pCR).Our findings show network deregulated specific patterns are pCR within each subtype.